7.375
0.87%
-0.065
Editas Medicine Inc stock is currently priced at $7.375, with a 24-hour trading volume of 428.07K.
It has seen a -0.87% decreased in the last 24 hours and a -33.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $7.39 pivot point. If it approaches the $7.24 support level, significant changes may occur.
Editas Medicine Inc Stock (EDIT) Financials Data
Editas Medicine Inc (EDIT) Revenue 2023
EDIT reported a revenue (TTM) of $78.12 million for the quarter ending December 31, 2023, a +296.34% rise year-over-year.
Editas Medicine Inc (EDIT) Net Income 2023
EDIT net income (TTM) was -$153.22 million for the quarter ending December 31, 2023, a +30.49% increase year-over-year.
Editas Medicine Inc (EDIT) Cash Flow 2023
EDIT recorded a free cash flow (TTM) of -$136.90 million for the quarter ending December 31, 2023, a +24.56% increase year-over-year.
Editas Medicine Inc (EDIT) Earnings per Share 2023
EDIT earnings per share (TTM) was -$2.05 for the quarter ending December 31, 2023, a +36.14% growth year-over-year.
Editas Medicine Inc Stock (EDIT) Latest News
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The Motley Fool
1 Beaten-Down Stock With 55% Upside, According to Wall Street
The Motley Fool
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The Motley Fool
The Latest Analyst Ratings For Editas Medicine
Benzinga
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Zacks Investment Research
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
About Editas Medicine Inc
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):